Skip to main content
Sign inSign up

ADSA Society

IssuesFor AuthorsAdvertisingNewsHelp

ADSA Society

Article Contents

Download PDF

Remimazolam, an ultra-short-acting benzodiazepine, is a new intravenous anesthetic used for sedation and general anesthesia. Because remimazolam is primarily metabolized by carboxylesterases in the liver and other tissues including the lung and has metabolites with little or no bioactivity, its anesthetic effect is not significantly influenced by renal dysfunction. Therefore, remimazolam may be considered an appropriate agent for hemodialysis patients and may have added benefits beyond midazolam and propofol. Remimazolam has also been suggested to cause less cardiac depression than propofol. This case report presents an 82-year-old female hemodialysis patient with chronic heart failure who underwent partial glossectomy for squamous cell carcinoma of the tongue under general anesthesia with remimazolam and remifentanil. Hemodynamic control was stable during the anesthetic, which was safely completed without any adverse events and resulted in a rapid, clear emergence without flumazenil. Remimazolam and remifentanil may be appropriate as first-line general anesthetic agents for hemodialysis patients with heart failure.

Keywords: Remimazolam; Anesthetic management; General anesthesia; Hemodialysis; Heart failure; Oral surgery; Remifentanil
  • Download PDF
Copyright: © 2023 by the American Dental Society of Anesthesiology

Get Email Alerts

Article Contents
ANPR logo
AboutIssuesAuthor InformationSubscriptions

ADSA Society

eISSN: 1878-7177

ISSN: 0003-3006

Powered by PubFactory